Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography

Kawashiro, Shohei; Mori, Shinichiro; Yamada, Shigeru; Miki, K.; Nemoto, Kenji; Tsuji, Hiroshi; Kamada, Tadashi

doi:10.1259/bjr.20160790

Cited by 23 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical therapy for volume reduction and making the space between GTV and organs at risk may help improve LC. Moreover, spot scanning irradiation, which has been already introduced at our facility, potentially allows the dose to be increased while maintaining safety 14 . In this study, spot scanning irradiation was used for the last patient (3%).…”

Section: Discussionmentioning

confidence: 99%

Long‐term outcomes of skull base chordoma treated with high‐dose carbon‐ion radiotherapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background We evaluated the long‐term efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for skull base chordoma, a rare neoplasm. Methods Thirty‐four patients with skull base chordoma who were treated with C‐ion RT were prospectively enrolled and analyzed retrospectively. C‐ion RT was delivered with 60.8 Gy (relative biological effectiveness [RBE]) in 16 fractions at four fractions per week. Results The median follow‐up period was 108 months. The 5‐ and 9‐year local control rates were 76.9% and 69.2%, respectively. The 5‐ and 9‐year overall survival rates were 93.5% and 77.4%, respectively. Regarding grade 3 or more severe late reactions, one patient developed a grade 3 mucosal ulcer, two developed grade 4 ipsilateral optic nerve injuries, and one developed a grade 5 mucosal ulcer at 9 years and 3 months after C‐ion RT. Conclusion C‐ion RT with 60.8 Gy (RBE)/16 fractions is a promising treatment option for inoperable skull base chordoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term outcomes of skull base chordoma treated with high‐dose carbon‐ion radiotherapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…2 Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China. 3 Gunma University Heavy Ion Medical Center, Maebashi, Japan.…”

Section: Abbreviationsmentioning

confidence: 99%

“…Carbon ion radiotherapy (CIRT) has emerged as a viable treatment option for unresectable pancreatic cancer in the last decades [1][2][3][4]. A multi-institutional study recently reported promising clinical outcomes in the overall survival and local control, which are superior to those obtained with conventional chemoradiation therapy or chemotherapy alone [1].…”

Section: Introductionmentioning

confidence: 99%

Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer

Kubota

Okamoto

et al. 2021

Radiat Oncol

View full text Add to dashboard Cite

Background Daily anatomical deviations may distort the dose distribution in carbon ion radiotherapy (CIRT), which may cause treatment failure. Therefore, this study aimed to perform re-planning to maintain the dose coverage in patients with pancreatic cancer with passive scattering CIRT. Methods Eight patients with pancreatic cancer and 95 daily computed tomography (CT) sets were examined. Two types of adaptive plans based on new range compensators (RCs) (AP-1) and initial RCs (AP-2) were generated. In AP-2, each beam was optimized by manually adjusting the range shifter thickness and spread-out Bragg peak size to make dose reduction by < 3% of the original plan. Doses of the original plan with bone matching (BM) and tumor matching (TM) were examined for comparison. We calculated the accumulated dose using the contour and intensity-based deformable image registration algorithm. The dosimetric differences in respect to the original plan were compared between methods. Results Using TM and BM, mean ± standard deviations of daily CTV V95 (%) difference from the original plan was − 5.1 ± 6.2 and − 8.8 ± 8.8, respectively, but 1.2 ± 3.4 in AP-1 and − 0.5 ± 2.1 in AP-2 (P < 0.001). AP-1 and AP-2 enabled to maintain a satisfactory accumulated dose in all patients. The dose difference was 1.2 ± 2.8, − 2,1 ± 1.7, − 7.1 ± 5.2, and − 16.5 ± 15.0 for AP-1, AP-2, TM, and BM, respectively. However, AP-2 caused a dose increase in the duodenum, especially in the left–right beam. Conclusions The possible dose deterioration should be considered when performing the BM, even TM. Re-planning based on single beam optimization in passive scattering CIRT seems an effective and safe method of ensuring the treatment robustness in pancreatic cancer. Further study is necessary to spare healthy tissues, especially the duodenum.

show abstract

“…108 Heavy particles, by protons and carbon ions, are emerging as promising treatment RT modality in radioresistant cancers, [109][110][111][112][113][114][115][116] such as pancreatic tumours. [117][118][119][120][121] Proton therapy, thanks to its intrinsic physical selectivity, allows delivering dose to the target with no exit dose in the beam path. This translates in a lower dose to surrounding organs and in the possibility of increasing the dose to the target volume with theoretically lower toxicity and better local outcomes.…”

Section: Radiotherapymentioning

confidence: 99%

<p>Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress</p>

Barcellini¹,

Peloso²,

Pugliese³

et al. 2020

OTT

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of death in the Western world, and it is estimated to become the second leading cause of tumour-related mortality in the next 10 years. Among pancreatic cancers, ductal adenocarcinomas are by far the most common, characterised by a challenging diagnosis due to the lack of initial and pathognomonic clinical signs. In this scenario, non-metastatic locally advanced pancreatic cancer (LAPC) accounts for a large proportion of all new pancreatic ductal adenocarcinoma diagnoses. There is no consensus on a common definition of LAPC. Still, it usually includes tumours that are not resectable due to vascular involvement. As of today, treatment is limited, and the prognosis is very unfavourable. Curative-intent surgery remains the gold-standard even if often jeopardized by vascular involvement. Continuing progress in our understanding of LAPC genetics and immunology will permit the development of different treatments, targeted or combined, including radiation therapy, hadrontherapy, targeted immunotherapies or new chemotherapies. A multidisciplinary approach combining various fields of expertise is essential in aiming to limit disease progression as well as patient outcome. Using a narrative literature review approach, the manuscript explores the most up-to-date knowledge concerning locally advanced pancreatic ductal adenocarcinoma management.

show abstract

Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography

Cited by 23 publications

References 28 publications

Long‐term outcomes of skull base chordoma treated with high‐dose carbon‐ion radiotherapy

Long‐term outcomes of skull base chordoma treated with high‐dose carbon‐ion radiotherapy

Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer

<p>Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress</p>

Contact Info

Product

Resources

About